The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2024Investigating the Early Events in Parkinson’s Disease Pathobiology through Longitudinal Evaluation of Asymptomatic Carriers of Alpha-synuclein Mutations
Study Rationale: Essentially nothing is known about the sequence of biological and physiological events that ultimately lead to the clinical manifestations of Parkinson’s disease (PD). The existence...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024First-in-human Phase 1a Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending doses of SB-0110 after Oral Administration in Healthy Subjects
Study Rationale: Although levodopa is an effective treatment for Parkinson’s disease (PD), it has a debilitating on-target side effect of dyskinesia. An optimal PD therapy would selectively activate...
-
Research Grant, 2024Determining Optimal Cognitive Measures and Clinical Trial Endpoints in Lewy Body Disorders
Study Rationale: People with Lewy body disorders, including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), often experience cognitive impairment that can impact function, independence...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Alterations in DNA Repair Mechanisms in Parkinson’s Disease Neurons and their Correlation with Clinical Variables
Study Rationale: Preserving the fidelity of genetic information is essential for life. Consequently, all organisms have developed efficient systems for repairing DNA damage. One of the consequences of...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Assessing the Safety and Efficacy of a Novel Enzyme Inhibitor in Reducing Neuroinflammation and Enhancing Neuroprotection in Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is characterized by neuroinflammation and the loss of dopamine neurons. Recently, epoxy-fatty acids have been shown to be neuroprotective in preclinical...
-
iPSC Phenotyping Environmental Exposure Program, 2024Establishing a Proof-of-concept, Automated Platform for Studying the Interactions of Genetic and Environment-based Toxicity in Human Cell Models of Parkinson’s Disease
Study Rationale: Many studies of Parkinson’s disease (PD) focus on investigating the disease’s genetic component. Yet only about 22% of PD diagnoses carry a genetic association. Increasing evidence...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.